The global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market was valued at US$ 9591.9 million in 2023 and is anticipated to reach US$ 24730 million by 2030, witnessing a CAGR of 14.7% during the forecast period 2024-2030.

Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx).

Report Scope

The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Report

Report Metric	Details
Report Name	Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market
Accounted market size in 2023	US$ 9591.9 million
Forecasted market size in 2030	US$ 24730 million
CAGR	14.7%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	PCR In-situ Hybridization Immunohistochemistry Sequencing Others
Segment by Application	Oncology Neurological Disorders Cardiovascular Disease Immunological Disorders Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market growing?

Ans: The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market witnessing a CAGR of 14.7% during the forecast period 2024-2030.

What is the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market size in 2030?

Ans: The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market size in 2030 will be US$ 24730 million.

Who are the main players in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market report?

Ans: The main players in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market are Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer

What are the Application segmentation covered in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market report?

Ans: The Applications covered in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market report are Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Others

What are the Type segmentation covered in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market report?

Ans: The Types covered in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market report are PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 PCR

1.2.3 In-situ Hybridization

1.2.4 Immunohistochemistry

1.2.5 Sequencing

1.2.6 Others

1.3 Market by Application

1.3.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Oncology

1.3.3 Neurological Disorders

1.3.4 Cardiovascular Disease

1.3.5 Immunological Disorders

1.3.6 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Perspective (2019-2030)

2.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Growth Trends by Region

2.2.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Region (2019-2024)

2.2.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Region (2025-2030)

2.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Dynamics

2.3.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Trends

2.3.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers

2.3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Challenges

2.3.4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players by Revenue

3.1.1 Global Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players by Revenue (2019-2024)

3.1.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Players (2019-2024)

3.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue

3.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Ratio

3.4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue in 2023

3.5 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Key Players Head office and Area Served

3.6 Key Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Solution and Service

3.7 Date of Enter into Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Breakdown Data by Type

4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Type (2019-2024)

4.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Type (2025-2030)

5 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Breakdown Data by Application

5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Historic Market Size by Application (2019-2024)

5.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)

6.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024)

6.4 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)

7.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024)

7.4 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)

8.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2019-2024)

8.4 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)

9.2 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024)

9.4 Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (2019-2030)

10.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024)

10.4 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Qiagen NV

11.1.1 Qiagen NV Company Detail

11.1.2 Qiagen NV Business Overview

11.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction

11.1.4 Qiagen NV Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

11.1.5 Qiagen NV Recent Development

11.2 GE Healthcare

11.2.1 GE Healthcare Company Detail

11.2.2 GE Healthcare Business Overview

11.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction

11.2.4 GE Healthcare Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

11.2.5 GE Healthcare Recent Development

11.3 Agilent Technologies

11.3.1 Agilent Technologies Company Detail

11.3.2 Agilent Technologies Business Overview

11.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction

11.3.4 Agilent Technologies Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

11.3.5 Agilent Technologies Recent Development

11.4 F Hoffman La Roche

11.4.1 F Hoffman La Roche Company Detail

11.4.2 F Hoffman La Roche Business Overview

11.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction

11.4.4 F Hoffman La Roche Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

11.4.5 F Hoffman La Roche Recent Development

11.5 Foundation Medicine

11.5.1 Foundation Medicine Company Detail

11.5.2 Foundation Medicine Business Overview

11.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction

11.5.4 Foundation Medicine Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

11.5.5 Foundation Medicine Recent Development

11.6 Thermo Fisher Scientific Inc.

11.6.1 Thermo Fisher Scientific Inc. Company Detail

11.6.2 Thermo Fisher Scientific Inc. Business Overview

11.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction

11.6.4 Thermo Fisher Scientific Inc. Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

11.6.5 Thermo Fisher Scientific Inc. Recent Development

11.7 Leica Biosystems Nussloch GmBH

11.7.1 Leica Biosystems Nussloch GmBH Company Detail

11.7.2 Leica Biosystems Nussloch GmBH Business Overview

11.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction

11.7.4 Leica Biosystems Nussloch GmBH Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

11.7.5 Leica Biosystems Nussloch GmBH Recent Development

11.8 Pfizer

11.8.1 Pfizer Company Detail

11.8.2 Pfizer Business Overview

11.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Introduction

11.8.4 Pfizer Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

11.8.5 Pfizer Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Thermo Fisher Scientific Inc

Leica Biosystems Nussloch GmBH

Pfizer Inc

List of Tables

Table 1. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of PCR

Table 3. Key Players of In-situ Hybridization

Table 4. Key Players of Immunohistochemistry

Table 5. Key Players of Sequencing

Table 6. Key Players of Others

Table 7. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Region (2019-2024)

Table 11. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Region (2025-2030)

Table 13. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Trends

Table 14. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers

Table 15. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Challenges

Table 16. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints

Table 17. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Players (2019-2024)

Table 19. Global Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) as of 2023)

Table 20. Ranking of Global Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product Solution and Service

Table 24. Date of Enter into Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Type (2019-2024)

Table 28. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Type (2025-2030)

Table 30. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Application (2019-2024)

Table 32. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Market Share by Application (2025-2030)

Table 34. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country (2025-2030) & (US$ Million)

Table 49. Qiagen NV Company Detail

Table 50. Qiagen NV Business Overview

Table 51. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product

Table 52. Qiagen NV Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024) & (US$ Million)

Table 53. Qiagen NV Recent Development

Table 54. GE Healthcare Company Detail

Table 55. GE Healthcare Business Overview

Table 56. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product

Table 57. GE Healthcare Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024) & (US$ Million)

Table 58. GE Healthcare Recent Development

Table 59. Agilent Technologies Company Detail

Table 60. Agilent Technologies Business Overview

Table 61. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product

Table 62. Agilent Technologies Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024) & (US$ Million)

Table 63. Agilent Technologies Recent Development

Table 64. F Hoffman La Roche Company Detail

Table 65. F Hoffman La Roche Business Overview

Table 66. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product

Table 67. F Hoffman La Roche Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024) & (US$ Million)

Table 68. F Hoffman La Roche Recent Development

Table 69. Foundation Medicine Company Detail

Table 70. Foundation Medicine Business Overview

Table 71. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product

Table 72. Foundation Medicine Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024) & (US$ Million)

Table 73. Foundation Medicine Recent Development

Table 74. Thermo Fisher Scientific Inc. Company Detail

Table 75. Thermo Fisher Scientific Inc. Business Overview

Table 76. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product

Table 77. Thermo Fisher Scientific Inc. Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024) & (US$ Million)

Table 78. Thermo Fisher Scientific Inc. Recent Development

Table 79. Leica Biosystems Nussloch GmBH Company Detail

Table 80. Leica Biosystems Nussloch GmBH Business Overview

Table 81. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product

Table 82. Leica Biosystems Nussloch GmBH Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024) & (US$ Million)

Table 83. Leica Biosystems Nussloch GmBH Recent Development

Table 84. Pfizer Company Detail

Table 85. Pfizer Business Overview

Table 86. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product

Table 87. Pfizer Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024) & (US$ Million)

Table 88. Pfizer Recent Development

Table 89. Research Programs/Design for This Report

Table 90. Key Data Information from Secondary Sources

Table 91. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Type: 2023 VS 2030

Figure 3. PCR Features

Figure 4. In-situ Hybridization Features

Figure 5. Immunohistochemistry Features

Figure 6. Sequencing Features

Figure 7. Others Features

Figure 8. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Application: 2023 VS 2030

Figure 10. Oncology Case Studies

Figure 11. Neurological Disorders Case Studies

Figure 12. Cardiovascular Disease Case Studies

Figure 13. Immunological Disorders Case Studies

Figure 14. Others Case Studies

Figure 15. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Report Years Considered

Figure 16. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Region: 2023 VS 2030

Figure 19. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Players in 2023

Figure 20. Global Top Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue in 2023

Figure 22. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Country (2019-2030)

Figure 24. United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Canada Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Country (2019-2030)

Figure 28. Germany Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Region (2019-2030)

Figure 36. China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Australia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Country (2019-2030)

Figure 44. Mexico Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Brazil Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Country (2019-2030)

Figure 48. Turkey Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Qiagen NV Revenue Growth Rate in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

Figure 51. GE Healthcare Revenue Growth Rate in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

Figure 52. Agilent Technologies Revenue Growth Rate in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

Figure 53. F Hoffman La Roche Revenue Growth Rate in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

Figure 54. Foundation Medicine Revenue Growth Rate in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

Figure 55. Thermo Fisher Scientific Inc. Revenue Growth Rate in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

Figure 56. Leica Biosystems Nussloch GmBH Revenue Growth Rate in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

Figure 57. Pfizer Revenue Growth Rate in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Business (2019-2024)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions